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Abstract
Background: Asthma is a disease that affects all ages, races and ethnic groups. Its incidence is increasing both in
Westernized countries and underdeveloped countries. It involves inflammation, genetics and environment and therefore,
proteins that exacerbate the asthmatic, allergic phenotype are important. Our laboratory purified and cloned a histamine
releasing factor (HRF) that was a complete stimulus for histamine and IL-4 secretion from a subpopulation of allergic donors’
basophils. Throughout the course of studying HRF, it was uncovered that HRF enhances or primes histamine release and IL-
13 production from all anti-IgE antibody stimulated basophils. In order to further delineate the biology of HRF, we
generated a mouse model.
Methodology/Principal Findings: We constructed an inducible transgenic mouse model with HRF targeted to lung
epithelial cells, via the Clara cells. In antigen naı ¨ve mice, overproduction of HRF yielded increases in BAL macrophages and
statistical increases in mRNA levels for MCP-1 in the HRF transgenic mice compared to littermate controls. In addition to
demonstrating intracellular HRF in the lung epithelial cells, we have also been able to document HRF’s presence
extracellularly in the BAL fluid of these transgenic mice. Furthermore, in the OVA challenged model, we show that HRF
exacerbates the allergic, asthmatic responses. We found statistically significant increases in serum and BAL IgE, IL-4 protein
and eosinophils in transgenic mice compared to controls.
Conclusions/Significance: This mouse model demonstrates that HRF expression enhances allergic, asthmatic inflammation
and can now be used as a tool to further dissect the biology of HRF.
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Introduction
We identified a histamine releasing activity that was found in
late phase fluids from nasal lavages, bronchoalveolar lavage (BAL)
fluids and skin blister fluids that directly induced histamine release
from basophils isolated from a subpopulation of allergic donors
[1]. After purification and cloning, this histamine releasing factor
(HRF) was found to be identical to translationally controlled tumor
protein (TCTP), which is also known as p23 [2–4]. This
recombinant molecule was found to have the same properties as
the originally described HRF derived from nasal secretions,
namely, an ability to induce histamine release from selected
donors, HRF-responders (HRF-R). This protein is ubiquitously
expressed as an intracellular protein. HRF has no leader sequence,
therefore, how it gets secreted was elusive until Amzallage et al
documented that HRF or as it is alternatively known, TCTP, was
secreted by an ER/Golgi-independent route [5]. Furthermore,
they documented that secreted HRF/TCTP comes from a pre-
existing intracellular pool and co-distributes with TSAP6, a
member of a family of proteins that are involved in vesicular
trafficking and secretory processes [6,7].
Homologs of HRF have been described in parasites including
Plasmodium falciparum, Wucheria bancrofti, Brugiia malea and Schistosoma
Mansinai, all of which possess mast cell/basophil histamine releasing
activity [8–10]. HRF was initially described as a complete
secretogogue for histamine and IL-4 secretion from basophils of
allergic donors [11]. Initially, it was thought that these donors had a
certaintypeof IgE that interactedwith HRF to inducesecretion [2].
However, it was subsequently demonstrated that HRF primed all
basophils for histamine release as well as IL-4 and IL-13 secretion
regardless of the type of IgE [12]. Additional studies demonstrated
that HRF did not appear to directly interact with IgE [13,14]. HRF
was also shown to stimulate eosinophils to produce IL-8 and induce
an intracellular calcium response [15]. Moreover, HRF has been
shown to inhibit cytokine production from stimulated primary T
cells and the Jurkat T cell line [16] at the level of gene transcription
[16]. Furthermore, Kang et al have identified this molecule as a B
cell growth factor [17]. This group demonstrated that HRF bound
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recently, HRF was shown to stimulate bronchial epithelial cells to
produce IL-8 and GM-CSF [18]. Thus, HRF, in addition to
functioning as a histamine releasing factor, can modulate secretion
of cytokines from human basophils, eosinophils, T cells, B cells and
epithelial cells, firmly establishing HRF’s extracellular role.
The importance of the association of HRF with human allergic
disease has been previously documented in numerous publications.
It should be noted that while these observations were made with
crudeHRF,thesameexistswithrecombinantmaterial.Forinstance,
HRF has been found inhuman respiratorysecretions (BAL) and skin
blister fluids [1]. Furthermore, sensitivity to HRF was restricted to a
subpopulation of atopic individuals [19]. In a separate study of
ragweed allergic patients, there was a significant correlation between
the intensity of symptoms in the late phase reaction and basophil
histamine release to HRF [20]. In a third study, only basophils from
allergic asthmatics and not non-allergic asthmatics responded to
HRF. Of those allergic subjects who responded in vitro, methylcho-
line sensitivity and symptoms of asthma were highly correlated [21].
Sampson et al have shown that production of HRF also is associated
with clinical status of food allergy and atopic dermatitis [22]. Based
on these observations, we believe that HRF may be an important
element of the pathogenesis of asthmatic, allergic diseases. Since
HRF is present in late phase reaction fluids in vivo,i tm a yb e
contributing to mediator release that is found in the late response.
Further understanding of the biology of HRF may help explain the
varying severities of allergic disease.
Although HRF has been extensively investigated for many years,
most studies have been carried out in primary human or cultured
cells. Currently, there is no established animal model available to
further explore the function of HRF. One group from Taiwan
generated HRF knockout mice by targeted gene disruption [23].
However, HRF knock out mice were embryonic lethal. Since HRF
is ubiquitous and highly conserved, our approach has been to create
an inducible HRF mouse model using the Tet-On system. Since we
wantedtotargetHRFtothe lungs,weusedtheCC10promoterthat
is expressed in Clara cells of the lung epithelium. Here, we report
the phenotype of this HRF-inducible mouse.
Materials and Methods
Ethics Statement
All procedures performed on mice were in accordance with the
National Institutes of Health guidelines for humane treatment of
animals and were approved by the Johns Hopkins University
Institutional Animal Care and Use Committee (ACUC). The
ACUC protocol number is MO07M197.
Transgenic TRE-HRF-EGFP plasmid construction
The HRF transgenic plasmid was generated by the combination
of three main components. The first component is the pTRE-tight
vector, which contains a modified TRE (tet response element)
controlling the inducible expression of the gene of interest. The
second component is human HRF cDNA, which was cloned from
U937 cells by RT-PCR and confirmed by sequencing. The third
component is the pIRES2-EGFP vector (Clontech, Mountain
View, CA). The IRES2 (internal ribosome entry site) allows the
enhanced green fluorescent protein (EGFP) gene to be expressed
individually as a reporter protein along with HRF in order to
facilitate the recognition of expression of transgenic human HRF.
Generation of transgenic mice
Transgenic HRF mice were generated by pronuclear
injection of the transgenic plasmid described above by the
John Hopkins Transgenic Core. HRF transgenic mice were
crossbred with CC10-rtTA mice on a C57BL/6 background to
obtain double transgenic CC10-rtTA/HRF mice (transgene++)
for the functional experiments. All experiments shown in these
studies were completed during crossbreeding to reach pure
background at generation 10. Therefore each protocol was
completed with littermate control mice to account for
generational variety. Mice were used at 6–11 weeks of age.
All mice were housed in cages with microfilters in a specific
pathogen-free environment.
Identification of transgenic mice
The presence or absence of the transgene in the resulting
animals and their progeny was determined using tail DNA and
PCR analysis. The primer sets used for PCR were EGFP-F, 59-
GAC GTA AAC GGC CAC AAG TT-39; EGFP-R, 59-GAA
CTC CAG CAG GAC CAT GT-39; TRE-HRF-F, 59-GTG TAC
GGT GGG AGG CCT AT-39; TRE-HRF-R, 59-GTT TCC
TGC AGG TGA TGG TT-39; and CC10-F, 59-ACT GCC CAT
TGC CCA AAC AC-39; CC10-R, 59-AAA ATC TTG CCA
GCT TTC CCC-39. The following PCR protocol was used: 95uC
for 5 min; 30 cycles of 95uC for 45 sec, 62uC (EGFP and HRF) or
60uC (CC10) for 45 sec, and 72uC for 45 sec; and a final extension
at 72uC for 5 min.
Experimental design
(1) Induction of transgene overexpression-Protocol I
All TRE-HRF-EGFP transgenic mice and CC10 control
mice were maintained on normal water until they were 6
weeks old. Then doxycycline (Dox) water at 1 mg/ml in 4%
sucrose kept in dark bottles to prevent light-induced
degradation was administrated for 3–4 weeks. Regular
drinking water was given to littermate controls for comparison
for the duration of the experiment (n=4211 per group).
(2) Ovalbumin (OVA) or PBS sensitization followed by OVA
challenge-Protocol II
The sensitization and challenge protocol was completed
as previously described [24]. Briefly, all mice were admin-
istrated Dox (1 mg/ml in 4% sucrose) in water on the first
day of the experiment (day -7) and through out the challenge
protocol to control for nonspecific Dox effects. Mice were
divided into four groups (n=629 per group): transgene++
and CC10 littermate sensitized with either OVA (Sigma, St
Louis, MO) or PBS on day 0 by intraperitoneal (i.p.)
injection of OVA (20 mg OVA adsorbed to 4 mg aluminum
hydroxide) or PBS as a control and then boosted with OVA
or PBS at day 5. Seven days later, all mice received a daily
intra nasal challenge of OVA (20 mg) for three consecutive
days.
(3) OVA sensitization followed by OVA (or PBS) challenge-
Protocol III
To further explore the role of HRF in the allergic diathesis
we design additional experiments that compared effects of
HRF on mice that are sensitized with OVA and then
challenged with OVA (as previously described in 2) or with
sham challenge of PBS (n=628 per group). The protocol was
otherwise the same as previously described.
Assessment of airway hyperresponsiveness (AHR)
Airway hyperresponsiveness (AHR) was assessed by methylcho-
line-induced airflow obstruction from conscious unrestrained mice
placed in a whole body plethysmograph (model PLY 3211, Buxco
Electronics Inc., Troy, New York, USA) [25]. In brief, mice were
HRF Transgenic Mice Phenotype
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computers using differential pressure transducers. Mice were
challenged for 3 min with a series of aerosolized methylcholine
inhalations. Enhanced pause (Penh) was monitored for 3 min after
each aerosol challenge by transducer (model TRD 5100, Buxco
Electronics Inc., Wilmington, NC) connected to preamplifier
modules (model MAX2270, Buxco Electronics Inc., Willington,
NC). Penh is a function of total pulmonary airway during the
respiratory cycle and is described by the following equation:
Penh=pause x (PEP/PIP), Pause, PEP and PIP are expiration
time, the peak expiratory pressure, and peak respiratory pressure,
respectively.
Lung and bronchoalveolar lavage samples
Lung tissues and BAL samples were obtained as previously
described [26]. Briefly, mice were anesthetized, the trachea was
isolated by means of blunt dissection, and small-caliber tubing was
inserted and secured in the airway. Two successive volumes of
1 ml of PBS were instilled and gently aspirated and pooled. The
BAL fluids were immediately centrifuged at 6000 rpm at 4uC for
5 min, and supernatants were stored at 280uC until use. After
removing the supernatant, the cells were counted manually in an
Improved Neubauer (Hausser Scientific, Horsham, PA) chamber.
Cytocentrifuged preparations (Cytospin 2, Cytospin, Shandon,
UK) were stained with May-Gru ¨nwald-Giemsa for differential cell
counts and examined under bright-field optical microscopy using a
light microscope, and corresponding digital images were captured
for subsequent analysis by a Spot CCD Camera driven by
Advanced Spot RT Software version 3.3 (Diagnostic Instruments
Inc., MI, USA). The lung was perfused with PBS through the right
ventricle until the lung was clean. The lung was excised for RNA
and protein analyses and/or inflated with fixative for histology.
Western blot analysis
Lung tissues were lysed with a lysis buffer (62.5 mM Tris-HCl
pH 7.5; 500 mM NaF; 100 mM Na3VO4, and proteinase
inhibitor cocktail, BD BioSciences, San Jose, CA) and then
centrifugated at 10,0006ga t4 uC for 30 min to obtain the cellular
proteins in the supernatant. The protein concentrations were
determined by BCA Protein Assay (Pierce Biotechnology Inc.,
Rockford, IL), and 20 mg of total protein from each sample were
boiled for 5 min and electrophoresed on 4–20% Tris-Glycine gels
(Invitrogen, Carlsbad, CA), transferred to nitrocellulose mem-
branes, and blocked in blocking buffer (150 mM NaCl in 10 mM
Tris, pH 7.5 containing 5% non-fat dry milk) for 1 hr at room
temperature. The membranes were blotted with anti-EGFP
(1:200; Santa Cruz Biotechnology, CA) or anti-HRF (in house
prepared monoclonal antibody [27]) at 4uC for at least 16 hours,
washed three times (20 mM Tris-HCl, pH 7.5, 137 mM NaCl,
and 0.1% Tween 20), incubated with HRP-conjugated goat anti-
mouse IgG secondary antibody (1:5000 dilution, GE Healthcar-
e,UK) for 1 h at room temperature, washed three times, followed
by the detection of signal with SuperSignalH West Pico
Chemiluminescent Substrate (Pierce Chemical Co., Rockford,
IL, USA). The density of each protein band was scanned using the
Bio-Rad Gel Doc system and the Quantity One 4.4.1 software
(Bio-Rad Laboratories, Hercules, CA) and compared by densi-
tometry to positive control.
Immunofluorescence microscopy
Freshly dissected lungs were fixed in Protocol Safefix II (Fisher
Scientific Co., Kalamazoo, MI) and embedded in paraffin. The
lung tissue sections (5 mm in thickness) were deparaffinized with
xyline, rehydrated gradually with graded alcohol solution (100%,
95%, and 80%), and then washed with deionized water and
immersed in 3% BSA for 1 h to block nonspecific binding. These
slides were then incubated with primary mouse anti-HRF
antibody at dilutions of 1:200 for 18 h at 4uC, washed twice in
PBS/Tween-20 solution, incubated with a Texas Red-conjugated
secondary antibody for 1 h at room temperature, and photo-
graphed with a fluorescent microscope. We chose anti-HRF
antibody to directly measure HRF. Therefore, an anti-GFP
antibody was unnecessary.
Histological examinations of lung tissues
Lung tissues were fixed in Protocol Safefix II (Fisher Scientific
Co.), and processed by AML Laboratories (Baltimore, MD).
Briefly, samples were embedded with paraffin, sectioned at 5 mm,
deparaffinized, dehydrated, and stained with hematoxylin and
eosin (H&E). In collaboration with Dr. Allen Myers, Head of the
Johns Hopkins Histologic Core, these specimens were examined
under bright-field optical microscopy using a light microscope, and
corresponding digital images were captured for subsequent
analysis by a Spot CCD Camera driven by Advanced Spot RT
Software version 3.3 (Diagnostic Instruments Inc.).
Reverse transcription polymerase chain reaction (RT-PCR)
Lungs were rapidly dissected and frozen on dry ice. For
extraction of total RNA, tissues were homogenized in 1 ml of ice-
cold TRIzol reagent (Invitrogen) and the total RNA was reverse-
transcribed into cDNA using a random hexamer and a GeneAmp
RNA PCR Kit (Applied Biosystems, Foster City, CA). PCR
analysis was performed by AccuPower PCR PreMix kit (BIO-
NEER, Alameda, CA) with each amplified primer set (EGFP-F,
59-GAC GTA AAC GGC CAC AAG TT-39; EGFP-R, 59-GAA
CTC CAG CAG GAC CAT GT-39; actin-F, TCC TGT GGC
ATC CAG GAA ACT; actin-R, GGA GGA ATG ATC CTG
ATC TTC; IL-4-F, 59-TCA TCG GCA TTT TGA ACG AG-39;
IL-4-R, 59-GAA TCC AGG CAT CGA AAA GC-39; IL-13-F, 59-
TCA GCC ATG AAA TAA CTT ATT GTT TTG T-39; IL-13-
R, 59-CCT TGA GTG TAA CAG GCC CAT TCT-39; MCP-1-
F, 59-ACC AGC CAA CTC TCA CTG AAG C-39; MCP-1-R,
59-CAG AAT TGC TTG AGG TGG TTG TG-39; MDC-F, 59-
CCT GGT GGC TCT CGT CCT TC-39; MDC-R, 59-CAG
GGG ATG GAG GTG AGT AA-39) under formulated
conditions. Amplified PCR products were analyzed by means of
electrophoresis, and the intensity of the bands and the ratio
of specific mRNA to b-actin were analyzed with the Bio-Rad
Gel Doc system and the Quantity 4.4.1 software (Bio-Rad
Laboratories).
Quantification of total IgE, OVA-specific IgE, and
chemokine levels
Blood drawn from the heart and BAL fluids were used for
measurement of total IgE levels with commercial mouse IgE
isotype-specific enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (BD Biosciences,
San Diego, CA). The levels of OVA-specific IgE in serum were
determined using a commercial ELISA per the manufacturer’s
instructions (MD Biosciences, Zu ¨rich Switzerland). IL-4 and
eotaxin levels of BAL fluids were quantitated using commercial
ELISA kits (R&D System, Inc, Minneapolis, MN) according to the
manufacturer’s instructions.
Statistical analysis
All experiments were repeated with multiple mice and matched
littermate controls as indicated by the n values in each experiment.
HRF Transgenic Mice Phenotype
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mean 6 S.E.M of each group. The statistical difference between
experimental groups was determined by Student’s t test. A p value
of less than 0.05 was considered statistically significant.
Results
Over Expression of Transgene and Phenotypic Analysis
(Protocol I)
Transgene expression. The schematic of the physical map
of the transgene is shown in Figure 1. We specifically did not
analyze copy numbers and integration sites of the transgene. Using
a combination of endonuclease digestion, PCR and nucleotide
sequencing, transgene integration sites in the genome can be
determined. However, knowing where the transgene is does not
prevent its segregation from its surrounding genes in the offspring,
and there are no practical values in the function of the transgene.
Ultimately the expression and function of the transgene needs to
be tested experimentally. The same is true with the copy numbers
of the transgene. Additionally, correlation between copy numbers
and expression and function of a transgene is not very clear.
After crossbreeding, both transgene++ and CC10 control mice
were treated with Dox at 1 mg/ml for 3–4 weeks. Regular
drinking water was also given to littermate controls for
comparison. Transgene expression was verified by both Western
blot and mRNA analysis of lung tissue. First, lung tissue lysates
were analyzed by Western blot for both EGFP and HRF
expression, as shown in Figure 2. The homology between mouse
and human HRF yields a cross-reaction and therefore Western
blots could not distinguish between native and transgenic HRF
expression, therefore, GFP was used as an additional marker of
transgene expression. Expression of HRF (Figure 2, Panel A) as
well as over expression of GFP (Figure 2, Panel B) in Dox treated
mice indicated that the Tet on system was operating effectively.
However we did see a modest, but not statistically significant
nonspecific Dox effect on HRF expression in CC10 mice.
Furthermore, there was a Dox-independent induction of HRF
when CC10 and ++ mice were fed with normal water (p=0.02).
However, GFP expression (Panels B and D) was not significantly
increased among these groups. Therefore, we do not think there is
evidence of promoter leakiness. Nevertheless, subsequent studies
were done comparing transgene++ and CC10 littermate controls
all fed Dox. RT-PCR analysis of lung tissues for EGFP expression
confirmed these results (Figure 2, Panel D). Of note, a
representative Western blot in the transgene++ or CC10 littermate
controls in the presence or absence of doxycycline is shown in
Figure 2, Panel C.
Phenotypic analysis. BAL cells were examined and there
was a significant increase in total cell counts in transgene++ mice
compared to CC10 mice following dox induction and the change
was primarily due to an increase in macrophages (p=0.04,
Figure 3). Of note, there are significant differences (p,0.001)
between transgenic ++ mice and CC10 littermate controls not fed
Dox in both total cells and macrophages. This may be due to the
increased HRF expression noted in Figure 2. However, given that
the Dox induction between transgenic ++ and control CC10 mice
was significantly different, we proceeded with experiments in
which all mice were fed Dox, as previously noted. Due to the
increase in macrophages, we investigated mRNA levels for MCP-
1. MCP-1 is known to be involved in the initiation of inflammation
[28]. As shown in the insert of Figure 3, there was a significant
increase in mRNA levels for MCP-1 in transgenic++ mice fed Dox
as compared to CC10 mice fed dox (p=0.04) and to transgenic++
mice fed regular water (p=0.05). Markers of TH2 inflammation
were also examined, including serum and BAL IgE levels, eotaxin,
IL4, IL5 and IL13 expression in lung tissues, but there were no
differences seen (data not shown). This is not surprising based on
the lack of TH2 cellular infiltrate in the lungs of the transgene++
mice (Figure 3), and the previously published studies. Specifically,
Teshima et al found that HRF caused eosinophil recruitment in
sensitized but not normal mice [29]. Additionally, Kang et al found
that in vivo administration of HRF increased total and Ag-specific
Ig synthesis, but these studies were done in the more
conventionally allergic BALB/c mice [17]. Thus, we had a
modest phenotype when the HRF transgene was turned on, but it
was not the allergic phenotype we initially expected. Therefore, we
proceeded to use our transgene++ mice in OVA sensitization and
challenge experiments to see if HRF enhanced the allergic
phenotype.
OVA (or PBS) Sensitization followed by OVA Challenge
(Protocol II)
The sensitization and challenge protocol was essentially the
same as described by Brusselle et al [24] and is outlined in
Material and Methods section. All mice were fed Dox 7 days prior
to and throughout the challenge protocol to control for nonspecific
Dox effects. The mice were divided into 4 groups: transgene++
and CC10 littermates sensitized with either OVA or PBS as a
control (n=629 per group). This model has been used extensively
and has generated brisk and consistent TH2 responses in the
murine lung [26]. After intranasal challenge, the phenotype of
each mouse was also assessed by BAL cell counts, histopathology
of bronchi and trachea, serum and BAL IgE levels, allergic
cytokine gene and protein expression in the BAL and/or lung
tissue.
Transgene expression. Transgene expression was
confirmed in each mouse as previously described and is shown
in Figure 4. Of note, HRF protein levels (Panel A) were increased
following OVA sensitization and challenge compared to PBS
sensitized OVA challenged litter mate controls in transgene++
mice (p=0.006) and in CC10 controls (p=0.02). The increases in
HRF are endogenous, and not promoter driven transgenic HRF
based on the similar GFP levels in the groups (Figure 4, Panel B).
This indicates that OVA sensitization increases naturally
occurring HRF, and supports HRF’s role in the antigen driven
allergic phenotype.
Lung cross-sections were subjected to immunoflourescent
staining to visualize HRF expression localized to the lung
epithelium. Immunoflourescent staining shown in Figure 5,
illustrates that HRF is up-regulated in the epithelium of
transgene++ mice fed Dox (Panels C and D) compared to
littermate controls (Panel A). Furthermore, OVA sensitization up-
regulates HRF in the lung epithelium (Panel D, compared to Panel
C). Nonspecific staining with no primary antibody (Panel B), as
well as additional experiments with an irrelevant antibody (not
shown) demonstrated no non-specific staining. The increase in
HRF expression could be due to an increase in the number of
Clara cells following antigen challenge or an increase in the
Figure 1. Schematic of the Physical Map of the HRF Transgene.
The plasmid construction is described in the Materials and Methods.
TRE (tet response element), pIRES (internal ribosome entry site), EGFP
(enhanced green fluorescent protein).
doi:10.1371/journal.pone.0011077.g001
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HRF is an abundant cellular protein and has been implicated in
cell cycle-related activities [30], but there are numerous reports of
its extracellular function [2,8–10,15–18]. In order to demonstrate
that HRF was additionally secreted in our mouse system, we
concentrated BAL samples 50-fold from OVA challenged
transgenic mice and compared to concentrated BAL from OVA
challenged CC10 littermate controls. The results of the Western
blot are shown in Figure 6. HRF expression levels in the transgenic
mice is greater than that from CC10 littermate controls. While
HRF is not visible in the controls due to the level of detection,
these expression levels of HRF in all BAL from transgenic mice are
consistent with the literature. In that case, a 100-fold concentra-
tion was necessary to detect HRF in human BAL of asthmatic
patients [18]. This demonstrates that HRF is secreted and
available to act extracellular to activate cells. Thus, our transgenic
mouse provides both an intracellular and extracellular expression
of HRF.
Lung Histology. OVA sensitized and challenged mice
demonstrated a marked cellular infiltrate in the bronchus when
stained with hematoxilin and eosin, as shown in Figure 7.
Eosinophils and enlarged and activated macrophages were seen in
transgenic++ mice sensitized and challenged with OVA (++/
OVA). This pattern was observed in comparison to CC10
littermate controls treated the same way (CC10/OVA), as well
Figure 2. Transgenic Protein and mRNA Expression for Mice in Protocol I. In all cases CC10 are control mice either fed Dox (Dox) or fed
regular water (no Dox). Transgenic mice (++) are either fed Dox (Dox) or are on regular water (no Dox). Each group has between 4 and 11 mice
(backcrosses 5–8). Panel A depicts the relative amount of HRF protein based on densitometric analysis of Western blots. Panel B is the relative amount
of GFP protein based on Western blots. Relative protein levels are expressed as a function of the positive control of each protein. Panel C is a
representative Western blot in the transgenic mice (++) or littermate controls (CC10) in the presence of doxycycline (Dox) or absence of doxycycline
(ND). Panel D shows mRNA for GFP relative to the housekeeping gene, beta actin.
doi:10.1371/journal.pone.0011077.g002
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differences in histology between these groups are concordant
with the differences in BAL cell counts.
BAL cell assessments. BAL cells from transgene++ mice
showed significant differences in the number of total cells as well as
the number of eosinophils that infiltrated the lung (Figure 8 Panel
A). Specifically, transgene ++ mice sensitized with PBS(++/PBS),
and then challenged with OVA have more total cells than CC10
littermate controls treated the same way(CC10/PBS) (p=0.04).
No significant differences in specific cell types were seen between
these 2 groups, although macrophages appear to be primarily
responsible, as was found in antigen naı ¨ve mice (Figure 3, Panel
A). These data recapitulate the previous data from Protocol I
indicating that HRF is capable of inducing the start of
inflammation by recruiting cells to the lung. These data suggest
that HRF operates independently of the effects of sensitization,
and perhaps initiates the early steps of inflammation through
macrophage recruitment. As expected, mice sensitized and
challenged with OVA had increased eosinophils compared to
littermate controls that received only PBS sensitization (p=0.04)
and the same was true for the transgene++ group comparisons
(p=0.005). Most importantly, the OVA sensitized and challenged
transgenic++ mice (++/OVA) had a significantly larger eosinophil
infiltration when compared to the CC10 litter mate controls
treated the same way(CC10/OVA) (p=0.02). These data support
the previously published data that HRF is involved with the
recruitment of eosinophils to the lung of allergen sensitized mice
[29]. Figure 8 Panel B, pictures BAL cells from individual mice
and illustrates the pattern seen for the groups as a whole shown in
the graph in Figure 8 Panel A.
IgE levels. Elevated IgE levels in the serum is a characteristic
feature commonly seen in allergic asthma patients and in mouse
models of allergen-induced asthma. IgE is important for the
functions of cells bearing the high affinity IgE receptor, such as
mast cells and basophils. As expected, we found significantly
increased serum IgE levels following OVA sensitization and
challenge in the transgene++ group and the CC10 group
compared to littermate controls sensitized with PBS (p=0.02
and p=0.003 respectively, Figure 9, Panel A). Interestingly,
transgene++ mice sham sensitized with PBS had significantly
higher serum IgE levels than CC10 controls (p=0.03). Similar to
the cell count assessment (Figure 8, Panel A) HRF exerted an effect
in the absence of allergen sensitization. There was no significant
difference between CC10 and transgene ++ mice challenged and
Figure 3. BAL Cell Counts for Mice in Protocol I. The average cell counts +/2 SEM from BAL supernatants for each group of mice is shown. Total
cells were counted using Erythrosin B stained under light microscopy. Cell differentials were done using cytospin slides of the BAL stained with Dif-
Quik. The insert shows mRNA for MCP-1 between various groups of mice. In all cases each group had between 4 and 11 mice (backcrosses 5–8).
doi:10.1371/journal.pone.0011077.g003
HRF Transgenic Mice Phenotype
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the sensitization and challenge. OVA specific IgE was significantly
increased following OVA sensitization and challenge, but not
changed by HRF expression in the transgene++ mice (data not
shown). These data suggest that HRF exerts its effect
independently of sensitization and suggest a role in the response
phase.
Furthermore, BAL IgE levels were significantly elevated in
transgene++ mice compared to CC10 littermate controls in both
OVA (p=0.02) and PBS (p=0.05) sensitized groups (Figure 9,
Panel B). While OVA sensitization and challenge elevated the
BAL IgE as expected, HRF over expression in the lung appears to
have a greater effect on these levels. Of note, all mice received
antigen to the lung and the combination of HRF and antigen gave
a strong local effect on BAL IgE. These data are consistant with
HRF being important in the response phase and support HRF’s
role in the allergic inflammation in the lung, given that native
HRF is seen in increased levels in the lung following OVA
sensitization and challenge (Figure 4).
Cytokine levels. Asthma is a chronic inflammatory disorder
of the lung and TH2 inflammation of the airway is a major
component of asthma. It has been demonstrated in animal models
of asthma that allergens can elicit TH2 inflammation and that IL-
4 is essential in this response. For example, in the presence of IL-4,
naı ¨ve CD4+ T cells differentiate into TH2 cells [31]. In order to
investigate the underlying molecular mechanism of the augmented
pulmonary inflammation in the HRF-inducible transgenic mouse
we investigated several cytokine and chemokine expression profiles
in the lung. As shown in Figure 10, when mice were sensitized and
challenged with OVA, transgene++ (++/OVA) mice had greater
mRNA levels of IL-4 (p=0.04) than CC10 littermate controls
treated the same way (CC10/OVA). There were no differences
observed in mRNA levels for eotaxin, IL-5 or IL-13 between these
groups (Figure 10). Protein levels for IL-4 were also measured from
BAL supernatants (Figure 10 Panel B). IL-4 protein levels were
Figure 4. Transgenic Protein Expression for Mice in Protocol II. Panel A depicts the relative amount of HRF protein based on densitometric
analysis of Western blots. Panel B is the relative amount of GFP protein based on Western blots. Relative protein levels are expressed as a function of
the positive control of each protein. In all cases mice were sensitized with PBS or OVA, then all mice were challenged with OVA. Each group had
between 6 and 9 mice (backcrosses 3–6).
doi:10.1371/journal.pone.0011077.g004
Figure 5. Immunoflourescent Staining for HRF in Mouse Lung.
The bronchi of 3 mice fed Dox to induce over expression of HRF are
shown. The genotype and sensitization reagent for each mouse is
shown in the top left corner of each panel. Panels A, C and D are stained
with rabbit anti-HRF antibody. Panel B illustrates the nonspecific
staining with secondary antibody alone.
doi:10.1371/journal.pone.0011077.g005
Figure 6. Expression of HRF Protein in BAL. Transgenic HRF mice
(++) and littermate control (CC10) mice were treated with doxycycline
water, sensitized and challenged with OVA, as previously described. BAL
supernatants were collected and pooled with 9 mice per pool, the IgG
was precleared by incubation with Protein A beads, and then the
supernatants were concentrated with a Centricon to 50-fold above the
original pool/volume. Concentrated samples were run a tris-glycine gel
with a recombinant HRF positive control. Western blotting was
completed using a monoclonal anti-HRF, as described for the whole
lung lysates.
doi:10.1371/journal.pone.0011077.g006
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in both CC10 and transgene++ mice following OVA sensitization
and challenge. Moreover, following OVA sensitization and
challenge transgenic mice (++/OVA) had significantly more IL-4
protein than CC10 mice (CC10/OVA) (p=0.05). The up
regulation of IL-4 as evidenced by both mRNA and protein in
the presence of HRF expression illustrates HRF’s role in
stimulating other cytokines central to the disease process.
Airway hyperreactivity (AHR). Airway physiology
abnormalities are a hallmark of asthma in human and animal
models of asthma. Methylcholine challenge was used to measure
airway reactivity. We saw an increase in airway reactivity
following sensitization and challenge with OVA, however, there
were no significant differences between littermate controls, except
at the top dose (50 mg/ml) between CC10/OVA vs. CC10/PBS
sensitized (data not shown). The over expression of HRF either by
Dox induced over expression, or by natural allergen induced up-
regulation did not appear to significantly effect the airway
reactivity to methylcholine compared to that seen with control
CC10 mice. This result is not unexpected since it is known that
AHR is IL-13 dependent [26] and IL-13 was not elevated in this
transgenic mouse model (Figure 10). Furthermore, IL-4, which we
do see increased in this model, does not induce AHR to
methylcholine. [32]. Since we did not see any changes in AHR
using Penh, we choose not to pursue invasive measurements of
AHR.
OVA Sensitization followed by OVA (or PBS) Challenge
(Protocol III)
To further explore the role of HRF in the allergic diathesis we
designed additional experiments that compare effects of HRF on
mice that are sensitized with OVA and then challenged with OVA
(as previously done in Protocol II) or with sham challenge of PBS
(n=628 per group). The absence of OVA challenge would
further dissect the role of HRF in the sensitization and response
phases. The protocol and phenotypic analysis were otherwise the
same as previously described.
Transgene expression. Transgene expression was
confirmed in each mouse as previously described and HRF
protein was up regulated following Dox administration on
transgene++ mice compared to CC10 littermate controls
(p=0.03). Of note again, is that HRF protein levels are
increased following OVA sensitization and challenge compared
to OVA sensitized PBS challenged litter mate controls in both
transgene++ (p=0.03) and CC10 mice (p=0.02, data not shown).
This indicates that OVA challenge increases naturally occurring
HRF, not unlike the results in Protocol II (Figure 4, Panel A)
where OVA sensitization increase HRF protein levels. GFP
protein levels were not significantly different following OVA
challenge (data not shown). This was previously shown in Protocol
II and indicates that endogenous HRF, not promoter driven
transgenic HRF, accounts for the increase in HRF protein.
Phenotype Analysis. Overall, results seen in the Protocol III
were similar to the data shown in the previous Protocol II between
transgenic++ and CC10 control mice OVA sensitized and
challenged. Namely, an increase in airway reactivity to
methylcholine challenge following sensitization and challenge
with OVA was seen, however, there were no significant
difference between littermate controls between transgene++
OVA versus PBS challenge. Also, IL-4 levels and eosinophil
numbers were elevated (data not shown). However, total cells and
macropahges were not significantly increased as seen in both
Protocol I, which are antigen naı ¨ve mice, and Protocol II which
were not sensitized with antigen. These data indicate that HRF
does not affect macrophage recruitment during OVA sensitization,
but HRF may initiate inflammation via macrophage recruitment
in the absence of sensitization.
IgE levels. As expected, serum IgE levels significantly
increased following OVA sensitization and challenge in both the
CC10 controls and the transgene++ group when compared to
littermate controls challenged with PBS (Figure 11, Panel A).
Transgene++ mice sham challenged with PBS (++/OVA-PBS)
had greater serum IgE levels than CC10 controls (CC10/OVA-
PBS)[p=.04]. Based on these data, as well as serum IgE levels
from Protocol II (Figure 9), HRF can increase serum IgE levels in
conjunction with either OVA sensitization or challenge.
Interestingly, transgene++ mice sensitized and challenged with
OVA (++/OVA-OVA) also had higher IgE levels than CC10 mice
treated the same way (CC10/OVA-OVA)[p=.01]. Unlike the
data in Protocol II (Figure 9), this difference could be due to
increase in strain purity between the protocols i.e. increased strain
purity revealed a previously unappreciated significance.
Additionally, OVA challenge is necessary for HRF to exert an
effect in the response phase as seen in the BAL levels (Figure 11,
Panel B). Specifically, there was no increase in BAL IgE in the
sham-sensitized transgene++ mice compared to the CC10 mice
treated the same way. This is in contrast to the results in Protocol
II, where sham-sensitized and OVA-challenged mice showed a
significant increase in BAL/IgE in the presence of HRF (Figure 9,
Panel B). BAL IgE levels between transgene++ and CC10 mice
sensitized and challenged with OVA had the same trend as seen in
Protocol II, but did not reach statistical significance (p=.07).
Discussion
In our transgenic HRF mouse model, we observed an induction
of HRF in the lung and corresponding increased numbers of
macrophages as well as levels of MCP-1 levels in the lungs. These
data were shown in Protocol I (Figures 2 and 3). MCP-1
expression is associated with many inflammatory conditions and
notably is elevated in the bronchial epithelium of asthmatics [28].
MCP-1 also is known to be involved with the initiation of
inflammation and is a chemoattractant for monocytes and
macrophages to areas of inflammation. Additionally, cultured
Figure 7. Mouse Lung Histology after OVA Challenge. The
mouse lungs were fixed, sectioned and stained with H and E. The
genotype and sensitization reagent of each mouse is shown above the
corresponding panel.
doi:10.1371/journal.pone.0011077.g007
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CSF [29]. Therefore, activated macrophages could be a source of
endogenous HRF found in the lung. In addition, OVA immunized
mice challenged with M-CSF caused macrophage infiltration and
HRF over production that was similar to OVA challenge. [29].
Furthermore, HRF has been shown to stimulate the secretion of
GM-CSF and IL-8 from bronchial epithelial cells [18]. Taken
together our data and the previously mentioned studies suggest
that HRF may increase airway inflammation by activating cells
such as epithelial cells or basophils (see below) to increase cytokine
and chemokine production which in turn up regulate the HRF
secretion and significantly contribute to the local inflammation in
the allergic, asthmatic lung.
We found that HRF levels in the lungs were increased by both
OVA sensitization and challenge. This increase was observed in
both HRF transgenic mice and CC10 control mice following
either OVA sensitization or OVA challenge (see Figure 4). The
immunoflourescent staining of the mouse lung (Figure 5) illustrates
both an increase in density and intensity of staining suggesting
both an increase in the number of cells expressing HRF and the
amount of HRF expressed. The increase in expression in
transgenic mice could be due to the increase in the number of
Clara cells following OVA challenge and sensitization. However,
GFP expression levels, as analyzed at protein and mRNA levels,
were not increased under these same conditions. Moreover, the
increases following OVA sensitization or challenge in the CC10
littermate controls could be due only to endogenous HRF. We
hypothesize based on this data as well as the previously mentioned
work, that antigen challenge could increase levels of HRF which
then acts on other cells to produce inflammatory cytokines.
We also showed after OVA sensitization and challenge that
HRF transgenic mice had increased levels of the TH2 cytokine
IL4, but not eotaxin, IL-5 or IL-13. IL-4 is necessary for the
induction of IgE production and the increases may be responsible
for the observed increase in total IgE. In addition, IL-4 has been
shown to play an important role in the migration of eosinophils
from the lung into the airway [27,28]. Moreover, previous studies
using human cells have shown that HRF is capable of inducing IL-
Figure 8. BAL Cell Counts. Panel A depicts the average cell counts +/2 SEM from BAL supernatants for each group of mice. Total cells were counted
using Erythrosin B stained under light microscopy. Cell differentials were done using cytospin slides of the BAL stained with Dif-Quik. Panel B shows
representativecytospinsfromthesemicewithgenotypeandsensitizationreagentonthetopofthecytospin.N=629micepergroup(backcrosses3–6).
doi:10.1371/journal.pone.0011077.g008
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production and histamine release was observed in response to
HRF from a subset of allergic donors basophils [9]. In addition,
HRF primed all donors’ basophils for IgE dependent mediator
release following antigen or anti-IgE stimulation. Not surprisingly,
in human work done in vitro, HRF has also been shown to cause
chemotaxis of eosinophils and secretion of IL-8 from allergic
donors [12]. In the present study, the allergen sensitized and
challenged mice also had increased numbers of infiltrating
eosinophils in their lungs (Figure 8). Although our previous work
in human cells showed HRF caused IL-13 secretion, we did not
see any changes in mRNA for IL-13 in the lung of transgenic HRF
mice, in the presence or absence of OVA sensitization and
challenge. IL-13 has been linked to airway hyper responsiveness
and mucous production in the same mouse model of allergy [23].
Therefore, given the lack of IL-13 expression in our transgenic
mice it is not surprising that we do not see increased AHR or
mucous production.
HRF has been shown to be present in the BAL of asthmatic
patients [18] as well as in the nasal lavage [1] and skin blister fluids
of patients with late phase allergic inflammation [33]. In the
present study, we could detect HRF in the BAL of the mice (see
Figure 6). The exact cell type that HRF activates in this model is
not known. However, given the fact that we see increased IL-4
levels and eosinopils recruited into the BAL, the mouse basophil is
a likely candidate. Mouse basophils have been shown to be the
cells responsible for secretion of IL-4 [34,35]. In fact, human and
mice basophils have been demonstrated to have more IL-4 per cell
than T cells and to be responsible for IL-4 secretion in allergic
reactions [36,37]. Future experiments are designed to test the
Figure 9. Serum and BAL IgE Levels. Panel A illustrates the average total serum IgE +/2 SEM for each group of mice. Panel B is the average IgE
levels detected in BAL supernatants from the same mice. IgE levels were measured by ELISA. N=629 mice per group (backcrosses 3–6).
doi:10.1371/journal.pone.0011077.g009
Figure 10. Cytokine and Chemokine Expression Levels. Panel A depicts relative mRNA levels compared to the housekeeping gene, beta actin,
using primers specific to each cytokine or chemokine noted. Equal amounts of RNA were used for this relative quantitation. Panel B shows protein
levels in BAL supernatants for IL-4 measured by ELISA. N=629 mice per group. Groups of mice are the same as described in Figure Legend 4
(backcrosses 3–6).
doi:10.1371/journal.pone.0011077.g010
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we are currently focused on the basophil.
HRF has been previouslyshown to activate epithelial cells[18] and
in our transgenic mouse model,HRF isexpressed in the Clara cellsof
the epithelium. However, Clara cells do not produce IL-4, therefore,
the observed increases in IL-4 are most likely due to secreted HRF.
Also, as previously mentioned, HRF is known to be secreted in an
ER/Golgi-independent manner [5]. Intracellular HRF levels have
been associated with increases in tumors [38]. Elevations of
intracellular HRF/TCTP that are associated with tumors would
not likely occur in the three week time frame that we use in our
model, and no gross changes in lung anatomy were observed.
HRF transgenic mice have increased total serum IgE levels
following either OVA sensitization or challenge (Figures 9 and 11),
suggesting a systemic effect of the over expression of HRF in the
lung. We also found increases in BAL IgE in transgenic HRF mice
following antigen challenge (Protocol II) in the absence of
sensitization, but not in the absence of antigen challenge (Protocol
III), suggesting that HRF is active in the response phase. This is in
accordancewiththeobservationthatOVAspecificIgEintheserum
is not increased in the HRF transgenic mice following OVA
sensitization and challenge when compared to CC10 littermate
controls treated the same way. Both observations suggest that HRF
elicits its effects in the response and not the sensitization phase.
In summary, endogenous HRF is up-regulated after either
allergen sensitization or challenge. Following OVA sensitization
and OVA challenge, we see the same trends, namely, increases in
IL-4 and eosinophils and no additional increases in AHR.
However, there are no differences in total cells and increases in
macropages following OVA sensitization and challenge with PBS.
This points to the fact that HRF does not exert its effect in the
sensitization phase alone. OVA challenge is necessary for HRF to
exert a local effect in the response phase as measured by increases
in BAL IgE levels. In contrast, either OVA sensitization or OVA
challenge will suffice for HRF to have an effect on serum IgE
levels. In general, HRF augments the inflammatory response to
allergens. This has been seen in vitro in human studies over the past
several years and is now seen in the mouse model of allergic
inflammation. Future studies with this transgenic mouse model will
elucidate the specific mechanisms of HRF’s actions on the
inflammatory process with particular emphasis on the mouse
basophil.
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